

19 September 2024

**Physiomics plc**  
**("Physiomics" or the "Company")**

**Notice of Results and Investor Presentation via Investor Meet Company**

Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it expects to release its audited results for the financial year ended 30 June 2024 during the last week of September 2024.

Dr Peter Sargent (CEO) and Dr Jim Millen (Non-Executive Chairman) will provide a live presentation relating to the Company's full year results and wider business update via Investor Meet Company on 7 October 2024 at noon BST.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 6 October 2024, 09:00 am BST, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet PHYSIOMICS PLC via:

<https://www.investormeetcompany.com/physiomics-plc/register-investor>

Investors who already follow the Company on the Investor Meet Company platform will automatically be invited.

**Enquiries:**

**Physiomics plc**

Dr Peter Sargent, CEO  
+44 (0)1235 841575

**Hybridan LLP (Broker)**

Claire Louise Noyce  
+44 (0) 203 764 2341

**Strand Hanson Ltd (NOMAD)**

James Dance & James Bellman  
+44 (0)20 7409 3494

**Notes to Editor**

**About Physiomics**

Physiomics plc combines cutting edge PKPD and QSP modelling and data science techniques, along with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys.

Our approach is to derive insight from all relevant data in order to provide decision making and optimisation during

Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design research across discovery, pre-clinical and clinical studies.

Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORGZGMLNRNGDZM